In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

The clinical use of bioactive adrenomedullin and proenkephalin A in detecting congestion, renal dysfunction and clinical outcomes in two independent acute heart failure cohorts

Session Moderated Poster Session - Acute heart failure

Speaker John Molvin

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Acute Heart Failure: Biomarkers
  • Session type : Moderated Posters

Authors : J Molvin (Malmo,SE), A Jujic (Malmo,SE), S Navarin (Rome,IT), O Melander (Malmo,SE), G Zoccoli (Rome,IT), O Hartmann (Hennigsdorf,DE), A Bergmann (Hennigsdorf,DE), J Struck (Hennigsdorf,DE), E Bachus (Malmo,SE), S Di Somma (Rome,IT), M Magnusson (Malmo,SE)

J Molvin1 , A Jujic2 , S Navarin3 , O Melander2 , G Zoccoli3 , O Hartmann4 , A Bergmann4 , J Struck4 , E Bachus2 , S Di Somma5 , M Magnusson1 , 1Skane University Hospital, Dept of Cardiology - Malmo - Sweden , 2Lund University, Dept of Clinical Sciences - Malmo - Sweden , 3Sapienza University of Rome - Rome - Italy , 4Sphingotec GmbH - Hennigsdorf - Germany , 5GREAT Network - Rome - Italy ,


In an acute heart failure (AHF) setting, proenkephalin A 119-159 (PENK) has emerged as a promising prognostic marker for predicting worsening renal function (WRF), while biologically active adrenomedullin (bio-ADM) has been proposed as a potential marker for congestion.

We examined the diagnostic value of bio-ADM in congestion and PENK in WRF, and investigated the prognostic value of bio-ADM and PENK regarding mortality, rehospitalisation, and length of hospital stay in two separate European AHF cohorts.

Bio-ADM and PENK were measured in 530 subjects hospitalized for AHF in two cohorts: the Swedish Heart and Brain Failure Investigation study - Malmö (HARVEST- Malmö) (n=322, 30.1% female; mean age 75.1 years; 12-months follow-up) and the GREAT Network Rome study (n=208, 54.8% female; mean age 78.5 years; no follow-up).

PENK was associated with WRF (AUC 0.65, p<0.001). In multi-variable logistic regression analysis of the pooled cohort, PENK showed an independent association with WRF (adjusted odds ratio [aOR] 1.74, p=0.004).

Bio-ADM was associated with peripheral oedema (AUC 0.71, p<0.001) which proved to be independent after adjustment (aOR 2.30, p<0.001).

PENK was predictive of in-hospital mortality (OR 2.24, p<0.001).

In the HARVEST-Malmö cohort, both PENK and bio-ADM were predictive of one-year mortality (aOR 1.34, p=0.038 and aOR 1.39, p=0.030). Furthermore, bio-ADM was associated with rehospitalization (aOR 1.25, p=0.007) and length of hospital stay (ß 0.702, p=0.005).

In two European AHF cohorts, bio-ADM and PENK perform as suitable biomarkers for early detection of congestion severity and WRF occurrence, respectively, and are associated with pertinent clinical outcomes.

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are